Diagnosis and management of non‐alcoholic fatty liver disease and related metabolic disorders: Consensus statement from theStudyGroup ofLiver andMetabolism,ChineseSociety ofEndocrinology (非酒精性脂肪性肝病与相关代谢紊乱诊疗共识——中华医学会内分泌学分会肝病与代谢学组)

Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in Western countries, affecting 20%-33% of the general population. Large population-based surveys in China indicate a prevalence of approximately 15%-30%. Worldwide, including in China, the prevalence of NAFLD has increased rapidly in parallel with regional trends of obesity, type 2 diabetes and metabolic syndrome. In addition, NAFLD has contributed significantly to increased overall, as well as cardiovascular and liver-related, mortality in the general population. In view of rapid advances in research into NAFLD in recent years, this consensus statement provides a brief update on the progress in the field and suggests preferred approaches for the comprehensive management of NAFLD and its related metabolic diseases.